Page last updated: 2024-11-06

floxuridine and Breast Neoplasms

floxuridine has been researched along with Breast Neoplasms in 198 studies

Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.

Breast Neoplasms: Tumors or cancer of the human BREAST.

Research Excerpts

ExcerptRelevanceReference
"We conducted a phase II study to determine the availability and safety of combination chemotherapy with weekly paclitaxel and doxifluridine (a capecitabine metabolite) in the treatment of advanced or recurrent breast cancer."9.13Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial. ( Asaishi, K; Doi, T; Inaba, M; Kimura, M; Nishimura, R; Okamoto, Y; Okuyama, N; Takeuchi, H; Tamaki, N; Tominaga, T; Yanagita, Y, 2008)
"We compared the therapeutic usefulness of doxifluridine (5'-DFUR) alone and a combination of 5'-DFUR plus cyclophosphamide (CPM), both of which are considered effective against advanced and recurrent breast cancer, to determine which treatment is more beneficial as postoperative adjuvant chemotherapy."9.10Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. ( Abe, O; Asaishi, K; Hirata, K; Ikeda, T; Kimijima, I; Koyama, H; Miura, S; Monden, Y; Morimoto, T; Noguchi, S; Nomura, Y; Ohashi, Y; Ota, J; Sonoo, H; Sugimachi, K; Toge, T; Toi, M; Tominaga, T; Yamaguchi, S, 2003)
"Twenty-four eligible patients (23 of whom were evaluated) with advanced and metastatic breast cancer were treated at the Saitama Cancer Center every 4 weeks with pirarubicin (30 mg/m2 i."9.09[Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer]. ( Higashi, Y; Inoue, K; Kurosumi, M; Suemasu, K; Tabei, T, 1999)
"We investigated efficacy and tolerance of chemotherapy with doxifluridine (5'-DFUR) and docetaxel (TXT) in advanced/recurrent breast cancer."9.09[A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer]. ( Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T, 2001)
"The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients."9.08[The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. ( Hayashi, K; Taniguchi, T; Toi, M; Tominaga, T, 1995)
"Between January 1993 and October 1995, 34 patients with anthracycline-resistant advanced breast cancer were treated with a combination chemoendocrine therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)."9.08A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer. ( Aiba, S; Endo, K; Fujii, T; Horiguchi, J; Iino, Y; Ishida, T; Kishi, S; Kusaba, T; Maemura, M; Morishita, Y; Ohwada, S; Shiozaki, H; Sugamata, N; Takano, A; Takei, H; Takeyoshi, I; Yokoe, T; Yokomori, T, 1998)
"Idarubicin 29 mg/m2 was given on day 1, doxifluridine 1500 mg and prednimustine 60 mg were given daily for 10-14 days (7 days/m2) in 17 patients with advanced breast cancer."9.07Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer. ( Alberto, P, 1993)
"Outpatients with advanced and recurrent breast cancer were treated by a combination therapy of the following drugs: doxifluridine (5'-DFUR) orally administered at a dose of 1200 mg/day; cyclophosphamide (CPA) orally given at dose of 100 mg/day; and tamoxifen (TAM) orally given at dose of 20 mg daily."9.07[Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs]. ( Irie, K; Kawahara, T; Okumura, T; Ota, J; Sakai, K; Shimoyama, T; Taguchi, T; Terasawa, T; Yamamoto, M; Yasutake, K, 1992)
"In Japan, the history of postoperative chemotherapy for breast cancer started with 5-fluorouracil (5-FU), launched in the 1980s."8.86Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. ( Nakayama, T; Noguchi, S, 2010)
"Capecitabine (Xeloda) is a prodrug of 5-FU used in the clinical management of advanced breast cancer."7.78Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda. ( Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z, 2012)
"We evaluated the safety and efficacy of capecitabine in 12 patients with anthracycline and/or taxane-resistant metastatic breast cancer on an outpatient basis."7.73[Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer]. ( Hamada, K; Kakihara, Y; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tachibana, M; Tagaya, N, 2005)
"To evaluate the feasibility and efficacy of weekly paclitaxel and 5'-DFUR combination therapy in advanced or recurrent breast cancer, 13 patients were enrolled in this pilot study."7.72[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer]. ( Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T, 2003)
"We evaluated the safety and efficacy of neoadjuvant chemotherapy with docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) in 5 patients with locally advanced breast cancer on an outpatient basis."7.72[Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer]. ( Hamada, K; Kakihara, Y; Kubota, K; Sawada, T; Tagaya, N, 2004)
"Docetaxel and capecitabine are being prescribed for the treatment of breast cancer."7.71Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. ( Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T, 2001)
"Two cases of metastatic breast cancer are reported in which endocrine chemotherapy with Toremifene + 5'-DFUR proved markedly effective."7.70[Endocrine chemotherapy (high-dose toremifene + 5'-DFUR) found markedly effective for 2 cases of metastatic breast cancer]. ( Kuroda, T; Mizutani, H; Nakamura, Y; Tadaoka, N; Takahashi, N, 1999)
"A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]."7.70[A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)]. ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999)
"A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)."7.70[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000)
"Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective."7.70[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000)
"A 72-year-old female with right breast cancer having multiple lung metastases was treated by combined administration of 5'-DFUR at 800 mg/day, and tamoxifen, at 20 mg/day, after standard radical mastectomy."7.69[A case of advanced breast cancer with multiple lung metastases responding well to postoperative combined administration of doxifluridine (5'-DFUR) and tamoxifen]. ( Akashi, Y; Hachiya, Y; Miyoshi, A; Noshiro, H; Tohma, H, 1994)
"Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported."7.69[Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997)
"We treated fifteen patients with recurrent breast cancer by a combination of mitoxantrone (8 mg/m i."7.69[Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer]. ( Katsumata, K; Kawasaki, M; Koyanagi, Y; Kusama, M; Moriwaki, R; Murano, A; Nagakawa, Y; Ogata, T; Shibata, K; Yamamoto, K, 1997)
"An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA."7.68[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]. ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991)
"A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer."7.67[A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985)
"In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life."6.705'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001)
"A total of 202 patients with advanced breast cancer were entered into two prospectively randomized Phase II trials conducted by the Eastern Cooperative Oncology Group, in an effort to identify promising agents and combinations for previously treated cases."6.65Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer. ( Colsky, J; Cummings, FJ; Gelman, R; Israel, L; Kuperminc, M; Skeel, RT; Tormey, D, 1981)
"A comparative study of 5'-DFUR 600 mg/day alone (C-arm) or in combination with TAM 30 mg/day (A-arm) or MPA 600 mg/day (B-arm) was carried out."6.38[A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer]. ( Aikawa, T; Hirai, T; Kotsuma, Y; Maeura, Y; Miyauchi, K; Takatsuka, Y; Yayoi, E, 1992)
"We report a postmenopausal recurrent breast cancer patient with triple negative disease who presented with right recurrent nerve palsy."5.35[Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report]. ( Jinta, E; Sakurai, T; Shimizu, S; Suzuma, T; Umemura, T; Yoshimura, G, 2008)
"It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted."5.33[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005)
"Two patients were diagnosed as advanced breast cancer with multiple bone metastases."5.33[Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)]. ( Kihara, M; Kontani, K; Yamauchi, A; Yokomise, H, 2005)
"For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice."5.32[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004)
"She was diagnosed as having advanced breast cancer of stage T4N3 (supraclavicular lymph node) M1 (bone)."5.31[Efficacy of combined chemoendocrine therapy with doxifluridine, cyclophosphamide, and fadrozole hydrochloride hydrate in a case of stage T4N3M1 breast cancer]. ( Fujii, T; Hanaoka, T; Ishida, K; Kawashima, K; Mihara, Y; Takahashi, T, 2000)
"To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice."5.31[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. ( Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002)
"Mitoxantrone (MIT) is a new anthraquinone anticancer agent."5.30[Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer]. ( Ichikawa, W; Iida, S; Miyanaga, T; Nihei, Z; Nishi, N; Osanai, T; Shimizu, C; Sugihara, K; Togo, S; Uetake, H; Yamashita, T, 1998)
"Brain metastases were also found."5.30[A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide]. ( Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Yoneda, K, 1999)
"Cancer cachexia is a common paraneoplastic syndrome in patients with advanced malignancies."5.30[Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model]. ( Arime, I; Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y, 1999)
"Mitoxantrone (MIT) is a new anthraquinone anti-cancer agent."5.29[Preoperative intra-arterial injection of mitoxantrone for locally advanced breast cancer]. ( Hirayama, R; Ichikawa, W; Mishima, Y; Miyanaga, T; Nihei, Z; Sawai, S; Shoji, Y; Yamashita, T; Yoshinaga, K, 1993)
"We conducted a phase II study to determine the availability and safety of combination chemotherapy with weekly paclitaxel and doxifluridine (a capecitabine metabolite) in the treatment of advanced or recurrent breast cancer."5.13Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial. ( Asaishi, K; Doi, T; Inaba, M; Kimura, M; Nishimura, R; Okamoto, Y; Okuyama, N; Takeuchi, H; Tamaki, N; Tominaga, T; Yanagita, Y, 2008)
"We conducted a randomized controlled study to evaluate the safety and usefulness of a combined treatment of radiotherapy and chemotherapy with doxifluridine (5'-DFUR) plus tamoxifen (TAM) as an adjuvant therapy for breast cancer patients after conservative surgery."5.10[Assessment of complications in a randomized controlled study on multimodality therapy for patients following breast-conserving surgery: Kansai Breast Cancer Radiotherapy Research Group (5'-KBR)]. ( Hiraoka, M; Inaji, H; Inoue, T; Kodama, H; Kono, M; Kono, N; Koyama, H; Sako, M; Suzuki, R, 2002)
"We compared the therapeutic usefulness of doxifluridine (5'-DFUR) alone and a combination of 5'-DFUR plus cyclophosphamide (CPM), both of which are considered effective against advanced and recurrent breast cancer, to determine which treatment is more beneficial as postoperative adjuvant chemotherapy."5.10Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery. ( Abe, O; Asaishi, K; Hirata, K; Ikeda, T; Kimijima, I; Koyama, H; Miura, S; Monden, Y; Morimoto, T; Noguchi, S; Nomura, Y; Ohashi, Y; Ota, J; Sonoo, H; Sugimachi, K; Toge, T; Toi, M; Tominaga, T; Yamaguchi, S, 2003)
"Twenty-four eligible patients (23 of whom were evaluated) with advanced and metastatic breast cancer were treated at the Saitama Cancer Center every 4 weeks with pirarubicin (30 mg/m2 i."5.09[Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer]. ( Higashi, Y; Inoue, K; Kurosumi, M; Suemasu, K; Tabei, T, 1999)
"We investigated efficacy and tolerance of chemotherapy with doxifluridine (5'-DFUR) and docetaxel (TXT) in advanced/recurrent breast cancer."5.09[A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer]. ( Aoyama, H; Asaga, T; Iwase, H; Kimura, M; Mitsuyama, S; Nishimura, R; Tominaga, T, 2001)
"The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients."5.08[The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. ( Hayashi, K; Taniguchi, T; Toi, M; Tominaga, T, 1995)
"Between January 1993 and October 1995, 34 patients with anthracycline-resistant advanced breast cancer were treated with a combination chemoendocrine therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)."5.08A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer. ( Aiba, S; Endo, K; Fujii, T; Horiguchi, J; Iino, Y; Ishida, T; Kishi, S; Kusaba, T; Maemura, M; Morishita, Y; Ohwada, S; Shiozaki, H; Sugamata, N; Takano, A; Takei, H; Takeyoshi, I; Yokoe, T; Yokomori, T, 1998)
"Idarubicin 29 mg/m2 was given on day 1, doxifluridine 1500 mg and prednimustine 60 mg were given daily for 10-14 days (7 days/m2) in 17 patients with advanced breast cancer."5.07Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer. ( Alberto, P, 1993)
"Outpatients with advanced and recurrent breast cancer were treated by a combination therapy of the following drugs: doxifluridine (5'-DFUR) orally administered at a dose of 1200 mg/day; cyclophosphamide (CPA) orally given at dose of 100 mg/day; and tamoxifen (TAM) orally given at dose of 20 mg daily."5.07[Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs]. ( Irie, K; Kawahara, T; Okumura, T; Ota, J; Sakai, K; Shimoyama, T; Taguchi, T; Terasawa, T; Yamamoto, M; Yasutake, K, 1992)
"In Japan, the history of postoperative chemotherapy for breast cancer started with 5-fluorouracil (5-FU), launched in the 1980s."4.86Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan. ( Nakayama, T; Noguchi, S, 2010)
"Capecitabine (Xeloda) is a prodrug of 5-FU used in the clinical management of advanced breast cancer."3.78Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda. ( Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z, 2012)
"The figures in patients with breast cancer were: 1,761 days (58."3.78[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR]. ( Taguchi, T, 1996)
"High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer."3.74[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007)
"A 42-year-old woman with multiple organ metastases from breast cancer was successfully treated with 5'-deoxy-5-fluorouridine (5'-DFUR) and hormonal therapy (leuprorelin+tamoxifen)."3.73[A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy]. ( Fukami, Y; Hasegawa, H; Hiromatsu, T; Itazu, K; Kawai, K; Komatsu, S; Sakamoto, E; Tabata, T, 2005)
"We evaluated the safety and efficacy of capecitabine in 12 patients with anthracycline and/or taxane-resistant metastatic breast cancer on an outpatient basis."3.73[Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer]. ( Hamada, K; Kakihara, Y; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tachibana, M; Tagaya, N, 2005)
"To evaluate the feasibility and efficacy of weekly paclitaxel and 5'-DFUR combination therapy in advanced or recurrent breast cancer, 13 patients were enrolled in this pilot study."3.72[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer]. ( Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T, 2003)
"Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clinically relevant concentrations in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clinical trials."3.72Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. ( Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ, 2004)
"We evaluated the safety and efficacy of neoadjuvant chemotherapy with docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) in 5 patients with locally advanced breast cancer on an outpatient basis."3.72[Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer]. ( Hamada, K; Kakihara, Y; Kubota, K; Sawada, T; Tagaya, N, 2004)
"Docetaxel and capecitabine are being prescribed for the treatment of breast cancer."3.71Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. ( Fujimoto-Ouchi, K; Tanaka, Y; Tominaga, T, 2001)
" The degree of synergism between docetaxel and two oral fluoropyrimidines, tegafur and 5'-deoxy-5-fluorouridine (5'-dFUrd), was investigated in the KPL-4 human breast cancer xenograft model."3.71Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts. ( Kunisue, H; Kurebayashi, J; Kurosumi, M; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, S, 2001)
"Gemcitabine and capecitabine are nucleoside analogues used in chemotherapy strategies for the treatment of breast cancer."3.71Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. ( Baldwin, SA; Cass, CE; Clarke, ML; Coupland, RW; Dabbagh, L; Jennings, LL; Koski, SL; Mackey, JR; Santos, CL; Vsianska, M; Young, JD, 2002)
" Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma."3.71gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001)
" To evaluate the mechanism of EGF-induced apoptosis, MDA-MB-468 breast cancer cells were examined by microscopy, flow cytometry, immunoblotting, enzyme assays, and affinity labeling after treatment with EGF, paclitaxel, or 5-fluoro-2'-deoxyuridine (5FUdR)."3.70Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis. ( Armstrong, DK; Blajeski, AL; Davidson, NE; Earnshaw, WC; Kaufmann, SH; Kottke, TJ; Martins, LM; Mesner, PW, 1999)
"Two cases of metastatic breast cancer are reported in which endocrine chemotherapy with Toremifene + 5'-DFUR proved markedly effective."3.70[Endocrine chemotherapy (high-dose toremifene + 5'-DFUR) found markedly effective for 2 cases of metastatic breast cancer]. ( Kuroda, T; Mizutani, H; Nakamura, Y; Tadaoka, N; Takahashi, N, 1999)
"A 60-year-old woman with her right breast cancer showing simultaneous and multiple liver metastases was initially treated with CEFT [cyclophosphamide (CPA), epirubicin (epi-ADM), 5-fluorouracil (5-FU), tamoxifen (TAM)]."3.70[A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)]. ( Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M, 1999)
"A left radical mastectomy was performed on a 53-year-old woman, diagnosed with left inflammatory breast cancer, after local arterial chemotherapy with cyclophosphamide (CPA), doxorubicin and 5-fluorouracil (5-FU)."3.70[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)]. ( Gen, T; Hara, Y; Igarashi, K; Jibiki, M; Kawasaki, T; Kikuchi, M; Kudoh, A; Noguchi, N; Yabata, E, 2000)
"Two cases of recurrent breast cancer are reported in which chemotherapy with mitoxantrone proved remarkably effective."3.70[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer]. ( Katagata, N; Matsuoka, T; Nomizu, T; Takenoshita, S; Tsuchiya, A; Watanabe, F; Yabuta, T; Yamaki, Y, 2000)
"Two hundred and sixteen T2 breast cancer patients were treated consecutively with surgery followed by 5'DFUR (600 mg/body/day) + tamoxifen (20 mg/body/day) for 2 years."3.70Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer. ( Akasaka, Y; Hata, Y; Nakanishi, Y; Ogita, M; Sasaki, F; Sawada, Y; Takahashi, H; Uchino, J; Yoshimoto, M, 2000)
"A 72-year-old female with right breast cancer having multiple lung metastases was treated by combined administration of 5'-DFUR at 800 mg/day, and tamoxifen, at 20 mg/day, after standard radical mastectomy."3.69[A case of advanced breast cancer with multiple lung metastases responding well to postoperative combined administration of doxifluridine (5'-DFUR) and tamoxifen]. ( Akashi, Y; Hachiya, Y; Miyoshi, A; Noshiro, H; Tohma, H, 1994)
"A 67-year-old female with extensive inflammatory breast cancer was treated with oral chemoendocrine therapy using 5'-deoxy-5-fluorouridine (5'-DFUR) 1,200 mg and medroxyprogesterone acetate (MPA) 1,200 mg before intra-arterial infusion chemotherapy, which made the extensive inflammatory skin lesion improve remarkably."3.69[A case of inflammatory breast cancer successfully treated with 5'-DFUR and MPA]. ( Ebihara, Y; Hirota, T; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Sekine, M; Serizawa, H, 1994)
"Twelve patients with liver metastases of breast cancer were treated with hepatic arterial infusion chemotherapy using 20-30 mg/body of epi-adriamycin (epi-ADM) every 2 weeks and continuous infusion of 250 mg/body/day of 5-fluorouracil (5-FU)."3.69[Intra-arterial infusion chemotherapy for liver metastases from breast cancer]. ( Furukawa, J; Kinuta, M; Maruhashi, S; Maruyama, H; Masuda, N; Matsui, S; Okamura, J; Ooi, H; Takiguchi, S; Tateishi, H; Tokunaga, M; Yano, H; Yayoi, E, 1996)
"Two cases of recurrent breast cancer, for which combined therapy using toremifene and oral chemotherapeutic agents were effective, are reported."3.69[Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment]. ( Asanuma, F; Miyagawa, T; Toyoda, H; Uesato, K; Yamada, Y, 1997)
"We treated fifteen patients with recurrent breast cancer by a combination of mitoxantrone (8 mg/m i."3.69[Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer]. ( Katsumata, K; Kawasaki, M; Koyanagi, Y; Kusama, M; Moriwaki, R; Murano, A; Nagakawa, Y; Ogata, T; Shibata, K; Yamamoto, K, 1997)
"An advanced breast cancer patient refractory to CAF (Cyclophosphamide, Adriamycin, 5-fluorouracil), 5-FU-Methotrexate sequential therapy and Tamoxifen was treated with the combination 5' DFUR, MMC, Etoposide and MPA."3.68[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer]. ( Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K, 1991)
"We have studied the effects of methotrexate (MTX-Glu1) and the polyglutamate derivatives of methotrexate (MTXPGs) with 2, 3, 4, and 5 glutamyl residues on the catalytic activity of thymidylate synthase purified from MCF-7 human breast cancer cells and on the kinetics of the ternary complex formation by 5-fluoro-2'-deoxyuridine 5'-monophosphate, folate cofactor, and thymidylate synthase."3.67Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. ( Allegra, CJ; Chabner, BA; Drake, JC; Jolivet, J; Lutz, R; Rodbard, D, 1985)
"We have investigated the role of dihydrofolate (H2PteGlu) accumulation in the inhibition of de novo purine synthesis by methotrexate (MTX) in human MCF-7 breast cancer cells."3.67Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate. ( Allegra, CJ; Baram, J; Drake, JC; Hoang, K; Yeh, GC, 1987)
"A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer."3.67[A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985)
" Following our former report in which the combination effects of mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) were clarified, combined applications of 4 drugs, vindesine (VDS), methotrexate (MTX), cisplatin (CDDP) and 5'-DFUR against 3 lines of human breast cancer (H-62, H-31, H-71), and one line each of gastric cancer (H-55) and colon cancer (H-110) xenografted into nude mice were evaluated in comparison with CAF (cyclophosphamide, adriamycin and 5-FU) therapy which is commonly used for breast cancer."3.67[Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T, 1987)
" In our previous studies with human gastrointestinal and breast cancers xenografted into nude mice, combination therapy with mitomycin C (MMC) and 5'-deoxy-5-fluorouridine (5'-DFUR) [I] or cisplatin (CDDP), vindesine (VDS) and 5'-DFUR [II] produced higher response rates than single-agent therapy with any one of these drugs."3.67[Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice]. ( Fujita, F; Fujita, M; Inaba, H; Sakamoto, Y; Shimozuma, K; Taguchi, T; Yamauchi, T, 1987)
" Therapeutic safety was evaluated by analyses of adverse events with the recommended dose."2.72[Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study]. ( Ikeda, M; Ishiguro, K; Kataoka, T; Komaki, K; Kurebayashi, J; Morimoto, T; Sonoo, H; Tanaka, K; Tangoku, A; Yoshizawa, K, 2006)
"Patients with relapsed, advanced breast cancer with evaluable lesions were given 5'-DFUR at 800 mg/day/body and CPA at 100 mg/day/body for 2 weeks, then underwent 2 weeks of drug withdrawal."2.72Clinical usefulness of oral combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR) and cyclophosphamide for metastatic breast cancer. ( Ando, Y; Hara, Y; Itoh, K; Itoh, Y; Iwase, H; Iwata, H; Karamatsu, S; Kobayashi, S; Kuzushima, T; Sugiura, H; Toyama, T; Yamashita, H; Yamashita, T, 2006)
"In all, 101 patients with metastatic breast cancer were enrolled in the study, and the data for 94 eligible patients of these were evaluated."2.71The potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer. ( Goto, T; Kasumi, F; Kutomi, G; Makita, M; Nishimura, S; Tada, K; Tanabe, M; Tokudome, N; Yoshimoto, M, 2003)
" The purpose of the present study was to examine the efficacy of long-term administration of 5'-DFUR/CPA for patients with recurrent breast cancer."2.71The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer. ( Aihara, N; Fukunaga, M; Iba, T; Kidokoro, A; Suda, M; Sugiyama, K, 2004)
"Capecitabine is a three-step prodrug that was rationally designed to be a more effective and safer alternative to its intermediate metabolite, 5'-deoxy-5-fluorouridine (5'-DFUR)."2.71Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR). ( Ebi, H; Igarashi, T; Kawada, K; Minami, H; Saeki, T; Sasaki, Y; Sigeoka, Y; Ueda, R; Usubuchi, N, 2005)
" The mean dosage per course of TXT was 58."2.71[Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)]. ( Fujii, K; Fujino, S; Higashide, S; Hori, T; Inamoto, T; Kan, N; Lee, CJ; Maruhashi, K; Mise, K; Mitsumori, M; Nishimura, S; Okamoto, M; Okamura, T; Sawai, S; Takemoto, Y; Yamauchi, A, 2005)
"In treating advanced or recurrent breast cancer, anthracycline-containing chemotherapy is used for palliation and to maintain quality of life."2.705'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer. ( Akao, S; Hiraide, H; Ishikawa, H; Maruyama, M; Matsumoto, F; Mochizuki, H; Okamura, H; Sato , K; Tabei, T; Tamakuma, S; Touma, M; Yagi, Y, 2001)
"We enrolled 1217 primary breast cancer patients and randomly assigned them into two treatment groups; one received six-month postoperative 5'-DFUR treatment by consecutive or intermittent administration, and the other surgery alone."2.70The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial. ( Abe, O; Abe, R; Asaishi, K; Enomoto, K; Hattori, T; Hayasaka, H; Hirata, K; Izuo, M; Kimijima, I; Koyama, H; Miura, S; Monden, Y; Morimoto, T; Nakazato, H; Nomura, Y; Ohashi, Y; Ota, J; Senoo, T; Sonoo, H; Sugimachi, K; Taguchi, T; Toge, T; Toi, M; Tominaga, T; Uchino, J; Watanabe, H; Yamaguchi, S; Yoshida, M, 2002)
"Chemotherapeutic management of breast cancers is a difficult task as they show significant differences in chemosensitivity."2.69Drug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro. ( Kazui, T; Kimura, T; Kobayashi, T; Sugimura, H; Suzuki, K; Uno, T; Yoshida, M; Yoshida, T, 1999)
"Mucositis and diarrhea are the dose-limiting toxicities when continuous infusions of FUdR and high-dose folinic acid are combined with oral hydroxyurea, effects that are consistent with the observed toxicities for FUdR when administered alone or in combination with leucovorin."2.67Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. ( Ahn, C; Akman, SA; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Newman, E; Raschko, JW; Somlo, G, 1994)
"5'-DFUR is a promising drug for breast cancer treatment, and its tablet form makes chemotherapy easier for the patient."2.67[Co-operative clinical evaluation of 5'-DFUR tablets for breast cancer at 31 institutions]. ( Inaji, H; Miura, S; Morimoto, K; Ohta, J; Taguchi, T; Ueda, N; Yayoi, K, 1992)
"5'-DFUR was administered orally to advanced or recurrent cancer patients at a daily dosage of 600-1200 mg divided into 3 or 4 times a day."2.66[Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients]. ( Imamura, Y; Irie, K; Nakamura, T; Suehiro, I; Yasutake, K; Yoshida, M; Yoshimura, Y, 1985)
"A total of 202 patients with advanced breast cancer were entered into two prospectively randomized Phase II trials conducted by the Eastern Cooperative Oncology Group, in an effort to identify promising agents and combinations for previously treated cases."2.65Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer. ( Colsky, J; Cummings, FJ; Gelman, R; Israel, L; Kuperminc, M; Skeel, RT; Tormey, D, 1981)
"A comparative study of 5'-DFUR 600 mg/day alone (C-arm) or in combination with TAM 30 mg/day (A-arm) or MPA 600 mg/day (B-arm) was carried out."2.38[A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer]. ( Aikawa, T; Hirai, T; Kotsuma, Y; Maeura, Y; Miyauchi, K; Takatsuka, Y; Yayoi, E, 1992)
"We report a postmenopausal recurrent breast cancer patient with triple negative disease who presented with right recurrent nerve palsy."1.35[Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report]. ( Jinta, E; Sakurai, T; Shimizu, S; Suzuma, T; Umemura, T; Yoshimura, G, 2008)
"It is well-known that breast cancer easily metastasizes to the bone, liver, pleura and lymph node, but rarely to the ovarium or peritoneum when chemotherapy is conducted."1.33[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report]. ( Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R, 2005)
"Two patients were diagnosed as advanced breast cancer with multiple bone metastases."1.33[Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)]. ( Kihara, M; Kontani, K; Yamauchi, A; Yokomise, H, 2005)
" The significance of treatment dosage and duration was obvious when 5-DFUR and Tam cotreatment was observed to be antagonistic in 3-day cultures of a second MCF-7 subline and T47D cells."1.33Combination of 5-deoxy-5-fluorouridine and tamoxifen show cell-type specific antagonistic and cooperative effects on cytotoxicity in human mammary carcinoma cells. ( Bollig, A; Du, QQ; Fan, ST; Liao, J; Sarkar, FH; Yu, B, 2005)
"Capecitabine is a new oral fluoropyrimidine derivative."1.33[Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)]. ( Ebi, H; Minami, H, 2005)
"ErbB2 overexpressing breast tumors have a poor prognosis and a high risk to develop chemoresistance to therapeutic treatment."1.335-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2. ( Bader, Y; Bernhaus, A; Fritzer-Szekeres, M; Gueorguieva, M; Krupitza, G; Leisser, C; Mader, RM; Madlener, S; Maier, S; Richter, S; Saiko, P; Schott, H; Strasser, S; Szekeres, T; Wesierska-Gadek, J, 2006)
"With a diagnosis of advanced breast cancer with skin invasion, she underwent right mastectomy with a free skin graft."1.32Massive mucinous carcinoma of the breast untreated for 6 years. ( Sakaguchi, K; Tsuchie, K; Yoneyama, F, 2003)
"For metastatic breast cancer patients who have hormone receptor-positive tumors, hormonal therapy aiming at optimal palliation and prolongation of life is the initial treatment of choice."1.32[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer]. ( Fuchimoto, S; Inagaki, M; Miyoshi, K; Nakagawa, T; Ohsaki, T; Ohtsuka, S; Yumura, M, 2004)
"We report a case of breast cancer with spinal and vertebral lesions."1.32[Successful combination therapy with 5'-DFUR and MPA for breast cancer with spinal and vertebral metastases]. ( Hashiguchi, H; Hirooka, Y; Kamasako, A; Nozaka, K; Ohgami, Y; Otani, S; Takebayashi, M; Tanida, O; Toyota, N; Wakatsuki, T, 2004)
" Administration of doxifluridine (5'-DFUR: Furtulon) (1,200 mg/day, 5 day continuous dosing followed by 2 day washout) and medroxyprogesterone acetate (MPA: Hysron H) (1,200 mg/day) was followed by chemotherapy consisting of intraarterial infusion of 100 mg of docetaxel (TXT: Taxotere), once monthly, via the left internal thoracic artery and left lateral thoracic artery."1.31[One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful]. ( Hara, A; Harada, T; Iwamoto, S; Izumi, N; Matsubara, C; Satake, K; Tsunematsu, I, 2002)
"She was diagnosed as having advanced breast cancer of stage T4N3 (supraclavicular lymph node) M1 (bone)."1.31[Efficacy of combined chemoendocrine therapy with doxifluridine, cyclophosphamide, and fadrozole hydrochloride hydrate in a case of stage T4N3M1 breast cancer]. ( Fujii, T; Hanaoka, T; Ishida, K; Kawashima, K; Mihara, Y; Takahashi, T, 2000)
"She was diagnosed with stage IV breast cancer."1.31[Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer]. ( Chino, Y; Ogata, M; Suzuki, Y; Tani, T; Ubukata, N; Yoshihara, K, 2001)
"To evaluate the antitumor efficacy against metastatic breast cancer of fluoropyrimidines alone and combined with other chemotherapeutic agents, we developed a murine model of breast cancer metastatic to the lung by orthotopically implanting MDA-MB-435S breast tumors into mice."1.31[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung]. ( Fujioka, A; Fukushima, M; Nakagawa, F; Nukatsuka, M; Ohshimo, H, 2002)
" Two months later a side effect of MPA, her body weight gain, was observed, and the dosage of MPA was reduced from 1,200 mg/day to 800 mg/day."1.31[A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA]. ( Otsuka, T; Tashiro, S; Terashima, Y, 2002)
"Mitoxantrone (MIT) is a new anthraquinone anticancer agent."1.30[Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer]. ( Ichikawa, W; Iida, S; Miyanaga, T; Nihei, Z; Nishi, N; Osanai, T; Shimizu, C; Sugihara, K; Togo, S; Uetake, H; Yamashita, T, 1998)
"Multiple liver and lung metastasis of breast cancer were diagnosed because of high CA 15/3 serum levels and normal gastrointestinal study."1.30[Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report]. ( Hoshino, K; Ikeda, H; Koyama, T; Morishita, Y; Nakamura, M, 1999)
"Brain metastases were also found."1.30[A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide]. ( Aoki, T; Kaise, H; Koyanagi, Y; Kusama, M; Matsunaga, T; Nakamura, Y; Nakayama, S; Yoneda, K, 1999)
"Cancer cachexia is a common paraneoplastic syndrome in patients with advanced malignancies."1.30[Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model]. ( Arime, I; Kunisue, H; Kurebayashi, J; Shimozuma, K; Sonoo, H; Tanaka, K; Udagawa, K; Yamamoto, S; Yamamoto, Y, 1999)
"The human MCF-7 breast cancer cell line was transfected with the dThdPase cDNA and expressed a 45 kDa protein that was detected with anti-dThdPase antibody."1.29Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. ( Bicknell, R; Harris, AL; Moghaddam, A; Patterson, AV; Stratford, IJ; Talbot, DC; Zhang, H, 1995)
"Mitoxantrone (MIT) is a new anthraquinone anti-cancer agent."1.29[Preoperative intra-arterial injection of mitoxantrone for locally advanced breast cancer]. ( Hirayama, R; Ichikawa, W; Mishima, Y; Miyanaga, T; Nihei, Z; Sawai, S; Shoji, Y; Yamashita, T; Yoshinaga, K, 1993)
"A 58-year-old woman with multiple organ metastases from breast cancer who had undergone radical mastectomy three years ago, was treated with oral 5'-DFUR 600 mg/day."1.29[A case of breast cancer with multiple organ metastases in which single low dose administration of 5'-DFUR proved effective]. ( Dohi, K; Gotoh, T; Kataoka, T; Nishiki, M; Okamoto, T; Sadamoto, S, 1993)
" In terms of ER stratification, ER(-) patients in the dosing groups showed increasing tendencies in S-phase and significant differences of G1- as well as G2+M phases."1.29[Influences of 5'-deoxy-5-fluorouridine (5'-DFUR) on cell cycle in patients with breast cancer]. ( Fujii, A; Hamano, K; Kamio, T; Katoh, T; Kimura, T; Muraki, H; Yamamoto, K, 1993)
"A 55-year-old woman with recurrent breast cancer treated with sequential mastectomies, chemo-and hormonal therapy of UFT, CPM and TAM, achieved remission."1.29[A case of recurrent breast cancer responding to long-term treatment with 5'-DFUR combined with MPA]. ( Kimura, M; Koida, T; Sekihara, M, 1996)
"We experienced 522 patients with breast carcinoma and 14 cases (2."1.29[A case resectable hepatic metastases of breast cancer following intrahepatic arterial chemotherapy]. ( Matsumine, T; Matsumoto, J; Minami, T; Takami, M; Takanishi, K, 1996)
"In contrast, estrogen-independent human breast cancer cells do not activate this programmed cell death pathway following estrogen ablation."1.28Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468. ( Armstrong, DK; Davidson, NE; Isaacs, JT; Ottaviano, YL, 1992)
"In case of breast cancer, it was 10 times higher than normal tissue."1.28[A study on pre-operative administration of 5'-DFUR in carcinomas of the gastric, breast, thyroid and colon]. ( Adachi, I; Douden, K; Hayashi, H; Hikishima, H; Iwa, T; Munemoto, Y; Okada, Y; Omura, K; Watanabe, Y, 1990)
" With use of these studies, a therapeutic ratio (concentration that prevented 25% clonal growth compared to untreated control of bone marrow divided by LD50 of tumor) was calculated for each drug in each tumor."1.275'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow. ( Armstrong, RD; Cadman, E, 1983)
" The optimal daily dosage was considered to be 800-1,200 mg/body/day."1.27[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study]. ( Abe, O; Kimura, K; Kimura, T; Kurihara, M; Nakao, I; Niitani, H; Ohta, K; Saito, T; Urushizaki, I; Yoshida, Y, 1985)
"1% of cases; however, it was easily reduced by decreasing the dosage or discontinuing administration of the drug."1.27[Phase II study of 5'-DFUR in gastrointestinal and breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1985)
"Minimal breast cancer was present in eight out of nine cases."1.27[Diagnosis of minimal breast cancer by diagnostic hormonal treatment]. ( Iwasa, Z; Matsunami, N; Saeki, Y; Yasutomi, M, 1986)
" Further pharmacological studies seem warranted to define the optimal dosage schedule and to obtain a better therapeutic index."1.27Phase II clinical evaluation of doxifluridine. ( Armand, JP; Bastit, P; Cappelaere, P; Fargeot, P; Fumoleau, P; Hurteloup, P; Keiling, R; Kerbrat, P; Metz, R; Schraub, S, 1986)
" This diarrhea, however, disappeared rapidly by decreasing the dosage or termination of treatment."1.27[A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)]. ( Tsukagoshi, S, 1987)
"5'-DFUR was administered orally to recurrent breast cancer patients at a daily dosage of 1,200 mg given 3 times a day for more than 8 weeks."1.27[Clinical trial of 5'-DFUR in patients with recurrent breast cancer]. ( Komaki, K; Konishi, Y; Miki, H; Monden, Y; Morimoto, T; Ooshimo, K; Tanaka, T; Uomine, Y; Yamakawa, T, 1988)
" 5'-DFUR was administered three or four times a day at a daily dosage of 600 to 1200 mg."1.27[Clinical phase II study of 5'-DFUR for cancer of the digestive organs by a cooperative study group]. ( Gocho, Y; Ishitani, K; Kogo, Y; Kouda, K; Koyama, R; Matsuda, M; Nagai, T; Niitsu, Y; Saijo, N; Urushizaki, I, 1985)
"Above all, some CR cases in breast cancer indicated remarkable superiority of this drug for monotherapy."1.27[Clinical effect of 5'-deoxy-5-fluorouridine (5'-DFUR)]. ( Fujita, M; Nakano, Y; Ohota, J; Taguchi, T, 1985)
"Samples from 11 patients with breast cancer treated with 5-FU-containing chemotherapy regimens were assayed."1.26The potential for clinical application of in vitro assays predicting 5-FU sensitivity in man. ( Ardalan, B; Cooney, D; Lippman, M; Macdonald, J; Schein, P, 1981)

Research

Studies (198)

TimeframeStudies, this research(%)All Research%
pre-199053 (26.77)18.7374
1990's66 (33.33)18.2507
2000's73 (36.87)29.6817
2010's4 (2.02)24.3611
2020's2 (1.01)2.80

Authors

AuthorsStudies
Zhang, C2
Han, M2
Zhang, F2
Yang, X1
Du, J2
Zhang, H3
Li, W2
Chen, S1
Wang, X1
Derissen, EJB1
Huitema, ADR1
Rosing, H1
Schellens, JHM1
Beijnen, JH1
Nishimura, R2
Tominaga, T12
Kimura, M3
Yanagita, Y1
Tamaki, N1
Asaishi, K3
Okamoto, Y2
Okuyama, N2
Takeuchi, H1
Inaba, M1
Doi, T1
Sakurai, T3
Umemura, T2
Jinta, E1
Suzuma, T1
Yoshimura, G2
Shimizu, S2
Nakayama, T1
Noguchi, S3
Saito, Y1
Suzuki, Y2
Tokuda, Y1
Ait-Tihyaty, M1
Rachid, Z1
Mihalcioiu, C1
Jean-Claude, BJ1
Kusama, M5
Hiraoka, M1
Koyama, H5
Inoue, T1
Kono, N1
Kono, M1
Kodama, H1
Inaji, H3
Sako, M1
Suzuki, R1
Harada, T1
Hara, A1
Tsunematsu, I1
Matsubara, C1
Izumi, N1
Iwamoto, S1
Satake, K1
Wang, Z1
Wang, S1
Zhu, F1
Ye, Y1
Yu, Y1
Qiao, X1
Mader, RM3
Schrolnberger, C1
Rizovski, B1
Brunner, M1
Wenzel, C1
Locker, G1
Eichler, HG1
Mueller, M1
Steger, GG1
Sawada, M1
Ono, Y2
Fukushima, M3
Kim, R1
Murakami, S2
Toge, T4
Miura, S4
Sugimachi, K2
Yamaguchi, S2
Hirata, K2
Monden, Y3
Nomura, Y3
Toi, M5
Kimijima, I2
Sonoo, H6
Ikeda, T1
Morimoto, T5
Ota, J3
Ohashi, Y3
Abe, O6
Zimmermann, A1
Walt, H1
Haller, U1
Baas, P1
Klein, SD1
Yoneyama, F1
Tsuchie, K1
Sakaguchi, K1
Sawada, T2
Kou, Y1
Xu, BH1
Zhang, YJ1
Zheng, X1
Wu, Q1
Wu, XT1
DAO, TL1
GRINBERG, R1
HEIDELBERGER, C1
ANSFIELD, FJ4
CURRERI, AR1
SULLIVAN, RD2
ZUREK, WZ1
WILSON, WL1
DELAGARZA, JG1
Akao, S3
Inoue, K4
Yoshimoto, M2
Tada, K1
Tokudome, N1
Kutomi, G1
Tanabe, M1
Goto, T2
Nishimura, S2
Makita, M1
Kasumi, F1
Tokunaga, Y1
Hosogi, H1
Nakagami, M1
Tokuka, A1
Ohsumi, K1
Tomono, H1
Kitamura, H1
Iwase, M1
Kuze, S1
Ohi, S1
Itoh, Y2
Nakazawa, H1
Fujita, H1
Oya, J1
Suzuki, O1
Sekishita, Y1
Shiono, T1
Kondo, S1
Kato, H1
Ishii, K1
Tsugawa, K1
Nakamura, M2
Ohnishi, I1
Miwa, K1
Pegram, MD1
Konecny, GE1
O'Callaghan, C1
Beryt, M1
Pietras, R1
Slamon, DJ1
Yamada, T1
Yuyama, Y1
Okazaki, Y1
Miyoshi, K1
Ohtsuka, S1
Inagaki, M1
Ohsaki, T1
Fuchimoto, S1
Yumura, M1
Nakagawa, T1
Iba, T2
Kidokoro, A2
Fukunaga, M2
Sugiyama, K2
Aihara, N2
Suda, M2
Otani, S1
Toyota, N1
Nozaka, K1
Wakatsuki, T1
Takebayashi, M1
Kamasako, A1
Tanida, O1
Hashiguchi, H1
Ohgami, Y1
Hirooka, Y1
Tagaya, N2
Kakihara, Y2
Hamada, K2
Kubota, K3
Tsubono, M1
Kaneko, I1
Kii, E1
Tanaka, T2
Murata, T1
Kamimura, K1
Deguchi, Y1
Nonogaki, H1
Yasumizu, R1
Suda, T1
Ebi, H2
Sigeoka, Y1
Saeki, T1
Kawada, K1
Igarashi, T1
Usubuchi, N1
Ueda, R1
Sasaki, Y1
Minami, H2
Sakamoto, E1
Hasegawa, H1
Komatsu, S1
Hiromatsu, T1
Itazu, K1
Tabata, T1
Kawai, K1
Fukami, Y1
Fujino, S1
Kan, N1
Lee, CJ1
Inamoto, T1
Mise, K1
Sawai, S2
Okamoto, M1
Hori, T1
Maruhashi, K1
Yamauchi, A2
Fujii, K1
Mitsumori, M1
Higashide, S1
Takemoto, Y1
Okamura, T1
Kihara, M2
Kontani, K1
Yokomise, H1
Bollig, A1
Du, QQ1
Fan, ST1
Yu, B1
Sarkar, FH1
Liao, J1
Nakagawa, A1
Mori, S1
Tachibana, M1
Suzuki, N1
Maier, S2
Strasser, S2
Saiko, P2
Leisser, C2
Sasgary, S1
Grusch, M1
Madlener, S2
Bader, Y2
Hartmann, J1
Schott, H2
Szekeres, T2
Fritzer-Szekeres, M2
Krupitza, G2
Yan, R1
Wan, L1
Pizzorno, G1
Cao, D1
Ikeda, M1
Tanaka, K3
Kurebayashi, J3
Tangoku, A1
Komaki, K2
Kataoka, T2
Ishiguro, K1
Yoshizawa, K1
Molina-Arcas, M1
Moreno-Bueno, G1
Cano-Soldado, P1
Hernández-Vargas, H1
Casado, FJ1
Palacios, J1
Pastor-Anglada, M1
Yamashita, T3
Yamashita, H1
Karamatsu, S1
Itoh, K1
Hara, Y2
Ando, Y1
Sugiura, H1
Kuzushima, T1
Toyama, T2
Iwata, H2
Kobayashi, S1
Iwase, H2
Bernhaus, A1
Gueorguieva, M1
Richter, S1
Wesierska-Gadek, J1
Yamamoto, Y2
Cummings, FJ2
Gelman, R1
Skeel, RT1
Kuperminc, M1
Israel, L1
Colsky, J1
Tormey, D1
Major, PP1
Egan, E1
Herrick, D2
Kufe, DW2
Ardalan, B1
Macdonald, J1
Cooney, D1
Lippman, M1
Schein, P1
Armstrong, RD2
Cadman, E2
Gesmonde, J1
Wu, T1
Gunner, L1
Fujita, F4
Fujita, M5
Taguchi, T11
Donehower, RC1
Allegra, JC1
Lippman, ME1
Chabner, BA2
Barberi-Heyob, M1
Weber, B1
Merlin, JL1
Dittrich, C1
de Bruijn, EA1
Luporsi, E1
Guillemin, F1
Patterson, AV1
Moghaddam, A1
Bicknell, R1
Talbot, DC1
Stratford, IJ1
Harris, AL1
Taniguchi, T1
Hayashi, K2
Kobayashi, J1
Ishikawa, H3
Asaumi, S1
Iwanami, K1
Matsumoto, H1
Kawashima, K2
Yokoe, T2
Iino, Y3
Morishita, Y3
Senga, O1
Miyakawa, M1
Hikita, H1
Horigome, N1
Kouzu, S1
Kuwae, K1
Hanaoka, T3
Yoshida, K1
Raschko, JW1
Akman, SA1
Leong, LA1
Margolin, KA1
Morgan, RJ1
Newman, E1
Somlo, G1
Ahn, C1
Doroshow, JH1
Tohma, H1
Noshiro, H1
Hachiya, Y1
Akashi, Y1
Miyoshi, A1
Koyanagi, Y4
Sekine, M1
Serizawa, H1
Ebihara, Y1
Hirota, T1
Nakamura, Y3
Matsunaga, T2
Yamamoto, T1
Funatsuka, M1
Naitoh, A1
Yano, S1
Tamura, K1
Alberto, P2
Takeshita, T1
Masuyama, H1
Tanahasi, T1
Suzuki, H1
Ichikawa, W2
Nihei, Z2
Shoji, Y1
Miyanaga, T2
Yoshinaga, K1
Hirayama, R1
Mishima, Y1
Okamoto, T1
Gotoh, T1
Sadamoto, S1
Nishiki, M2
Dohi, K1
Kimura, T3
Muraki, H1
Kamio, T1
Katoh, T2
Fujii, A1
Yamamoto, K2
Hamano, K1
Kurihara, T1
Higashi, Y2
Suemasu, K2
Kanoh, T1
Tabei, T3
Enomoto, K2
Abe, R2
Nakazato, H2
Koida, T1
Sekihara, M1
Masuda, N1
Yayoi, E4
Furukawa, J1
Maruhashi, S1
Tokunaga, M1
Takiguchi, S1
Matsui, S1
Yano, H1
Tateishi, H1
Kinuta, M1
Maruyama, H1
Ooi, H1
Okamura, J1
Matsumoto, J1
Minami, T1
Takami, M1
Takanishi, K1
Matsumine, T1
Yoshida, M4
Abe, S1
Kojima, M1
Soma, R1
Wagner, CR1
Ballato, G1
Akanni, AO1
McIntee, EJ1
Larson, RS1
Chang, S1
Abul-Hajj, YJ1
Nishibe, M1
Kuribayashi, H1
Sato, T1
Watanabe, I1
Nishihara, H1
Endo, M1
Fujimoto-Ouchi, K2
Matsumoto, T1
Tanaka, Y2
Ishitsuka, H1
Yamada, Y2
Miyagawa, T1
Toyoda, H1
Uesato, K1
Asanuma, F1
Katsumata, K1
Shibata, K1
Murano, A1
Kawasaki, M1
Moriwaki, R1
Nagakawa, Y1
Ogata, T1
Avril, N1
Dose, J1
Ziegler, S1
Jänicke, F1
Schwaiger, M1
Sugamata, N1
Maemura, M1
Takei, H1
Horiguchi, J1
Takeyoshi, I1
Ohwada, S1
Kusaba, T1
Ishida, T1
Yokomori, T1
Fujii, T2
Endo, K1
Shiozaki, H1
Aiba, S1
Takano, A1
Kishi, S1
Takatsuka, Y4
Shin, E1
Osanai, T1
Shimizu, C1
Uetake, H1
Iida, S1
Nishi, N1
Togo, S1
Sugihara, K1
Bajetta, E1
Biganzoli, L1
Carnaghi, C1
Di Bartolomeo, M1
Spagnoli, I1
Cassata, A1
Galante, E1
Mariani, L1
Stampino, CG1
Buzzoni, R1
Yamane, E1
Nanri, M1
Chimori, Y1
Oguro, A1
Fujita, Y1
Ikoma, H1
Nakagawa, H1
Yamada, M2
Maeda, N1
Iwatsuki, K1
Tsuzuki, T1
Hirayama, A1
Yamamoto, H2
Ikenaka, K1
Matsusaka, K1
Miyauchi, A1
Maeda, M1
Fujitake, S2
Maeda, Y3
Shimizu, M2
Nozaki, H2
Tohyama, M2
Kataoka, S2
Sumimura, J1
Morimoto, Y1
Miyazaki, M1
Ishikawa, S1
Nagai, I1
Kurosumi, M2
Kottke, TJ1
Blajeski, AL1
Martins, LM1
Mesner, PW1
Davidson, NE2
Earnshaw, WC1
Armstrong, DK2
Kaufmann, SH1
Senoo, T2
Takashima, S1
Hoshino, K1
Ikeda, H1
Koyama, T1
Tadaoka, N1
Mizutani, H1
Kuroda, T1
Takahashi, N1
Tashiro, H1
Takahashi, I2
Yamamura, S1
Ishikawa, T1
Yanaga, K1
Wakasugi, K1
Matsusaka, T1
Kume, K1
Suzuki, K1
Kazui, T1
Uno, T1
Kobayashi, T1
Yoshida, T1
Sugimura, H1
Kokufu, I2
Taniguchi, H2
Kim, YH2
Fukuda, K2
Yamamoto, M4
Yano, T2
Yamada, K2
Kitano, H2
Kaise, H2
Nakayama, S2
Yoneda, K1
Aoki, T2
Yamamoto, S2
Kunisue, H2
Udagawa, K1
Arime, I1
Shimozuma, K4
Tanaka, R1
Fukushima, H1
Sato, K1
Matsuda, M2
Goya, T1
Yasui, M1
Nishi, T1
Yamasaki, M1
Kishibuchi, M1
Yagyu, T1
Kawasaki, K2
Kiyono, T1
Nishiwaki, M1
Okuda, K1
Tsujitsuka, K1
Kano, Y1
Koga, T1
Ishimaru, K1
Sumiyama, M1
Harada, Y1
Ohuchi, N1
Ohnuki, K1
Amano, G1
Yoshida, R1
Furuta, A1
Ikegaki, H1
Kijima, G1
Satomi, S1
Kawasaki, T1
Yabata, E1
Gen, T1
Jibiki, M1
Kudoh, A1
Noguchi, N1
Igarashi, K1
Kikuchi, M1
Oura, S1
Tamaki, T1
Kokawa, Y1
Naito, Y1
Ishida, K1
Takahashi, T1
Mihara, Y1
Matsuoka, T1
Nomizu, T1
Yabuta, T1
Katagata, N1
Watanabe, F1
Yamaki, Y1
Tsuchiya, A1
Takenoshita, S1
Takahashi, H3
Todo, S2
Hata, Y1
Sasaki, F2
Ogita, M1
Uchino, J2
Akasaka, Y1
Nakanishi, Y1
Sawada, Y1
Mizutani, M1
Iwase, T1
Murai, H1
Watanabe, K1
Taguchi, K1
Watanabe, Y2
Kaiga, T1
Ueda, T1
Fujii, M1
Maruyama, S1
Okumoto, T1
Ino, H1
Kanaya, Y1
Otani, J1
Yokoyama, N1
Soda, M1
Sato , K1
Hiraide, H1
Tamakuma, S1
Maruyama, M1
Touma, M1
Okamura, H1
Matsumoto, F1
Yagi, Y1
Mochizuki, H1
Fukuda, Y1
Hirao, S1
Koyama, I1
Takatori, H1
Terakura, M1
Mayumi, K1
Tsukazaki, Y1
Kinoshita, H1
De Larco, JE1
Wuertz, BR1
Manivel, JC1
Furcht, LT1
Aoyama, H1
Mitsuyama, S1
Asaga, T1
Nakagomi, H1
Miyauchi, Y1
Okuda, J1
Muto, S1
Akaike, H1
Takahashi, M1
Mitui, T1
Ashizawa, I1
Chiba, S1
Nakazawa, M1
Imamura, K1
Otsuki, T1
Chino, Y1
Ubukata, N1
Yoshihara, K1
Tani, T1
Ogata, M1
Mackey, JR1
Jennings, LL1
Clarke, ML1
Santos, CL1
Dabbagh, L1
Vsianska, M1
Koski, SL1
Coupland, RW1
Baldwin, SA1
Young, JD1
Cass, CE1
Kitahara, S1
Ogata, H1
Katagiri, T1
Nonaka, K1
Shiba, T1
Nukatsuka, M2
Fujioka, A2
Nakagawa, F2
Ohshimo, H2
Hayasaka, H1
Izuo, M1
Watanabe, H1
Hattori, T1
Otsuka, T1
Terashima, Y1
Tashiro, S1
Basaki, Y1
Chikahisa, L1
Aoyagi, K1
Miyadera, K1
Yonekura, K1
Hashimoto, A1
Okabe, S1
Wierzba, K1
Miyamoto, H1
Yoshida, S1
Imatomi, M1
Saitoh, T1
Nakata, A1
Ota, D1
Misaka, T1
Matunaga, T1
Kitazato, K1
Meyer, JS1
Facher, R1
Schabel, FM1
Hoovis, ML1
Calabresi, P2
Morimoto, K1
Ohta, J1
Ueda, N1
Yayoi, K1
Koh, J1
Murayama, Y1
Sano, M1
Katai, H1
Maeda, K1
Sakai, S1
Yamamoto, O1
Hashimoto, M1
Hosoda, Y1
Sakai, K2
Irie, K3
Terasawa, T3
Shimoyama, T1
Kawahara, T3
Okumura, T2
Yasutake, K2
Tsumura, I1
Kobayakawa, K1
Miyauchi, K3
Aikawa, T2
Maeura, Y2
Hirai, T2
Kotsuma, Y2
Isaacs, JT1
Ottaviano, YL1
Tamm, I1
Cardinale, I1
Sehgal, PB1
Yoshinaka, K1
Yagi, M1
Ohtagaki, S1
Hrushesky, WJ1
Maeda, H1
Miyamoto, T1
Mochinaga, N1
Tsunoda, T1
Lokich, J1
Moore, C1
Anderson, N1
Bern, M1
Nishizawa, Y1
Imaoka, S1
Iwanaga, T1
Kaji, M1
Kitada, M1
Satomi, T2
Arai, Y1
Endo, T1
Miyake, Y1
Kido, C1
Munemoto, Y1
Omura, K1
Hikishima, H1
Okada, Y1
Hayashi, H1
Adachi, I1
Douden, K1
Iwa, T1
Allegra, CJ2
Drake, JC2
Lutz, R1
Rodbard, D1
Jolivet, J1
Kaysen, J1
Spriggs, D1
Kufe, D1
Hoang, K1
Yeh, GC1
Baram, J1
Kosaka, A1
Sumiyoshi, K1
Ando, J1
Berry, JP1
Lespinats, G1
Escaig, F1
Boumati, P1
Tlouzeau, S1
Cavellier, JF1
Galle, P1
Enomoto, T1
Watanabe, A1
Yoshida, Y2
Ogawa, N1
Niitani, H1
Kimura, K1
Saito, T1
Nakao, I1
Urushizaki, I2
Ohta, K1
Kurihara, M1
Kitamura, M1
Kosaki, G1
Okajima, K1
Tomita, K1
Yamaguchi, A2
Imamura, Y1
Yoshimura, Y1
Nakamura, T1
Suehiro, I1
Hoshino, A2
Ohara, K1
Kamiya, O2
Nagata, K1
Kawakubo, A1
Ozaki, Y1
Suzuki, A1
Ogasawara, T1
Sugiura, I1
Iwasa, Z1
Saeki, Y1
Matsunami, N1
Yasutomi, M1
Hurteloup, P1
Armand, JP1
Cappelaere, P1
Metz, R1
Kerbrat, P1
Keiling, R1
Fumoleau, P1
Fargeot, P1
Schraub, S1
Bastit, P1
Murakami, M1
Ota, K1
Yasue, M1
Kinoshita, T1
Hiraiwa, K1
Hachisuka, K1
Sakamoto, Y2
Inaba, H2
Yamauchi, T1
Pagana, TJ1
Somers, WR1
Tsukagoshi, S1
Jungi, WF1
Siegenthaler, P1
Mermillod, B1
Obrecht, JP1
Decoster, G1
Cavalli, F1
Yamakawa, T1
Konishi, Y1
Uomine, Y1
Miki, H1
Ooshimo, K1
Kogo, Y1
Kouda, K1
Ishitani, K1
Niitsu, Y1
Gocho, Y1
Koyama, R1
Nagai, T1
Saijo, N1
Wells, JJ1
Nostrant, TT1
Wilson, JA1
Gyves, JW1
Fujimoto, S1
Wang, Y1
Ogawa, M1
Nakano, Y1
Ohota, J1
Shingleton, WW1
Sedransk, N1
Johnson, RO1
Fennelly, JJ1
Fitzgerald, MX1
Ramirez, G1
DeConti, RC1
Kaplan, SR2
Papac, RJ1
Oldham, RK1
Siwarski, D1
McCoy, JL1
Plata, EJ1
Herberman, RB1
Miller, E1
Morrow, LB1
Burrow, GN1
Mulrow, PJ1

Reviews

11 reviews available for floxuridine and Breast Neoplasms

ArticleYear
Therapeutic usefulness of postoperative adjuvant chemotherapy with Tegafur-Uracil (UFT) in patients with breast cancer: focus on the results of clinical studies in Japan.
    The oncologist, 2010, Volume: 15, Issue:1

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast

2010
EXPERIMENTAL AND CLINICAL USE OF FLUORINATED PYRIMIDINES IN CANCER CHEMOTHERAPY.
    Cancer research, 1963, Volume: 23

    Topics: Breast Neoplasms; Carbon Isotopes; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Me

1963
Uridine phosphorylase in breast cancer: a new prognostic factor?
    Frontiers in bioscience : a journal and virtual library, 2006, Sep-01, Volume: 11

    Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycy

2006
[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:8

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Cachexia;

1996
[Diagnosis of breast carcinoma and locoregional lymph nodes with positron emission tomography].
    Der Radiologe, 1997, Volume: 37, Issue:9

    Topics: Blood Glucose; Breast Neoplasms; Female; Floxuridine; Humans; Lymph Nodes; Lymphatic Metastasis; Neo

1997
[Treatment strategy for recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophospha

1998
[Recent development of oral anti-cancer drugs for breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:3

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Clin

1999
[Thymidine phosphorylase as a prognostic factors of breast cancers].
    Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58 Suppl

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Disease-Free Survival; Female; Floxuridine; Human

2000
Rationale for adjuvant chemotherapy.
    Cancer, 1977, Volume: 39, Issue:6 Suppl

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carmustine; Cyclophosphamide; Cytarabine; Doxorubi

1977
[A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:5

    Topics: Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Female; Flox

1992
The multifrequency (circadian, fertility cycle, and season) balance between host and cancer.
    Annals of the New York Academy of Sciences, 1991, Volume: 618

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Renal Cell; Circadian Rhythm; Female; F

1991

Trials

37 trials available for floxuridine and Breast Neoplasms

ArticleYear
Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    British journal of clinical pharmacology, 2018, Volume: 84, Issue:6

    Topics: Activation, Metabolic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cytidine Triphosphate; Dea

2018
Efficacy of doxifluridine combined with weekly paclitaxel therapy in the treatment of advanced or recurrent breast cancer: results of the JMTO BC01 phase II trial.
    Anti-cancer drugs, 2008, Volume: 19, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival

2008
[Assessment of complications in a randomized controlled study on multimodality therapy for patients following breast-conserving surgery: Kansai Breast Cancer Radiotherapy Research Group (5'-KBR)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Drug Ad

2002
Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

2003
The potential for oral combination chemotherapy of 5'-deoxy-5-fluorouridine, a 5-FU prodrug, and cyclophosphamide for metastatic breast cancer.
    British journal of cancer, 2003, Nov-03, Volume: 89, Issue:9

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemothe

2003
The efficacy of long-term oral chemotherapy with 5'-deoxy-5-fluorouridine and cyclophosphamide for recurrent breast cancer.
    International journal of clinical oncology, 2004, Volume: 9, Issue:5

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast

2004
Pharmacokinetic and pharmacodynamic comparison of fluoropyrimidine derivatives, capecitabine and 5'-deoxy-5-fluorouridine (5'-DFUR).
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplas

2005
[Bi-weekly chemotherapy with medium-dose docetaxel for advanced and recurrent breast cancers (The 15th study of Keiji Breast Cancer Study Group)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:5

    Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Marr

2005
[Evaluation of safety and efficacy for bi-weekly Docetaxel and 5'-DFUR combination therapy in patients with advanced or recurrent breast cancer--Phase I study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:6

    Topics: Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Bone Ne

2006
Clinical usefulness of oral combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR) and cyclophosphamide for metastatic breast cancer.
    Breast cancer (Tokyo, Japan), 2006, Volume: 13, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

2006
Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine in metastatic breast cancer.
    Cancer, 1981, Aug-01, Volume: 48, Issue:3

    Topics: Antineoplastic Agents; Bleomycin; Breast Neoplasms; Cytarabine; Drug Evaluation; Drug Therapy, Combi

1981
[The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B

1995
Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea.
    Cancer chemotherapy and pharmacology, 1994, Volume: 35, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

1994
Phase II study of an oral combination of doxifluridine, prednimustine and idarubicin (FUPRIDA) for first line treatment of advanced breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:5

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Femal

1993
[A randomized controlled study of maintenance therapy with (2"R)-4'-O-tetrahydropyranyladriamycin for advanced and recurrent breast cancer. Clinical Study Group of THP for Breast Cancer in Japan].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:7

    Topics: Adult; Alopecia; Anorexia; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco

1996
[Survival and changes of clinical laboratory data in phase II study with 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:8

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Blood Cell Count; Breast Neoplasms; Cachexia;

1996
[The alteration of PyNPase activity in breast cancers due to preoperative oral administration of 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:6

    Topics: Administration, Oral; Adult; Antineoplastic Agents; Breast Neoplasms; Female; Floxuridine; Humans; M

1997
A combination chemoendocrine therapy of mitoxantrone, doxifluridine, and medroxyprogesterone acetate for anthracycline-resistant advanced breast cancer.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:3

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1998
Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer.
    Cancer, 1998, Sep-15, Volume: 83, Issue:6

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Proto

1998
[Clinical application of FdUrd to meningeal dissemination of malignant tumors].
    No shinkei geka. Neurological surgery, 1998, Volume: 26, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Drug Admin

1998
[Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox

1999
[Usefulness of low dose 5'-DFUR (5'-deoxy-5-fluorouridine) for advanced or recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Adm

1999
[Effects of DAC (doxifluridine, adriamycin, cyclophosphamide) chemotherapy in advanced breast cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:6

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclop

1999
Drug-induced apoptosis and p53, BCL-2 and BAX expression in breast cancer tissues in vivo and in fibroblast cells in vitro.
    Japanese journal of clinical oncology, 1999, Volume: 29, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Division; Drug

1999
[Clinical efficacy of low-dose weekly docetaxel combined with oral 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced or metastatic breast cancer: a pilot trial].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

2000
5'-deoxy-5-fluorouridine, medroxyprogestrone acetate and mitoxantrone hydrochloride for advanced or recurrent breast cancer.
    Breast cancer (Tokyo, Japan), 2001, Volume: 8, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

2001
[A phase I study of docetaxel (TXT) and doxifluridine (5'-DFUR) combination therapy in patients with advanced and recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Drug Admin

2001
[The efficacy of combination chemotherapy of 5'-deoxy-5-fluorouridine (5'-DFUR), cyclophosphamide (CPA) and medroxyprogesterone acetate (MPA) for bone metastasis in breast cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:7

    Topics: Adult; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Adm

2001
The effect of adjuvant 5'-deoxy-5-fluorouridine in early stage breast cancer patients: results from a multicenter randomized controlled trial.
    International journal of oncology, 2002, Volume: 20, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Disease-Free Survival; Female; Floxu

2002
Prognostic and predictive value of thymidine phosphorylase activity in early-stage breast cancer patients.
    Clinical breast cancer, 2002, Volume: 3, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Disease-Free S

2002
[Co-operative clinical evaluation of 5'-DFUR tablets for breast cancer at 31 institutions].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:7

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Diarrhea; Drug Administr

1992
[Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:9

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

1992
[Requirements for the randomized trial of i.a. vs. i.v. administration to reveal the impact of hepatic arterial infusion on survival in the treatment of liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:8 Pt 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Floxuri

1990
[Clinical trial of 5'-DFUR against various malignant tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:12

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug Adm

1985
[Clinical trial of 5'-deoxy-5-fluorouridine (5'-DFUR) in advanced cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:12

    Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Administration Schedul

1985
[Clinical trial of a new fluorinated pyrimidine, 5'-deoxy-5-fluorouridine (5'-DFUR)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:4 Pt 1

    Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Admin

1986
Adrenal function in patients treated with testosterone and fluorinated pyrimidines.
    The Journal of clinical endocrinology and metabolism, 1968, Volume: 28, Issue:2

    Topics: 17-Ketosteroids; Adenocarcinoma; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormon

1968

Other Studies

151 other studies available for floxuridine and Breast Neoplasms

ArticleYear
Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle.
    International journal of nanomedicine, 2020, Volume: 15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; DNA; Drug Carriers; Drug Delivery Syste

2020
Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer.
    Scientific reports, 2020, 12-16, Volume: 10, Issue:1

    Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Survival; DNA; Doxorubicin; Drug Delivery Syste

2020
[Doxifluridine, medroxyprogesterone acetate and cyclophosphamide (DMpC) combination therapy is effective against recurrent triple negative breast cancer--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Floxurid

2008
Combination therapy by trastuzumab with 5'-deoxy-5-fluorouridine and cyclophosphamide in patients with metastatic breast cancer.
    The Tokai journal of experimental and clinical medicine, 2009, Sep-20, Volume: 34, Issue:3

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplas

2009
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
    Breast cancer research and treatment, 2012, Volume: 133, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferat

2012
[Doxifluridine, medroxyprogesterone acetate and cyclophosphamide(DMpC)combination therapy found effective for case of chest wall recurrent breast cancer with bone and pleural metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophospha

2012
[One case of locally advanced breast cancer in which multidisciplinary treatment, chiefly, therapy with preoperative intraarterial infusion of docetaxel (TXT), was successful].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

2002
Expression of extracellular signal-regulated kinase and its relationship with clinicopathological characteristics of breast cancer.
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2002, Volume: 24, Issue:4

    Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Female; Floxuridine; Humans; Mitogen-Activated Pr

2002
Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
    International journal of clinical pharmacology and therapeutics, 2002, Volume: 40, Issue:12

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine

2002
[A case of advanced recurrent breast cancer responding to treatment with weekly docetaxel combined with doxorubicin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Combine

2003
Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis.
    International journal of oncology, 2003, Volume: 22, Issue:4

    Topics: Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; DNA, Complementary; Dose-Response Rela

2003
Effects of chlorin-mediated photodynamic therapy combined with fluoropyrimidines in vitro and in a patient.
    Cancer chemotherapy and pharmacology, 2003, Volume: 51, Issue:2

    Topics: Apoptosis; Breast Neoplasms; Carcinoma, Basal Cell; Floxuridine; Fluorouracil; Humans; Male; Mesopor

2003
Massive mucinous carcinoma of the breast untreated for 6 years.
    International journal of clinical oncology, 2003, Volume: 8, Issue:2

    Topics: Adenocarcinoma, Mucinous; Biopsy, Needle; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Floxurid

2003
[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr

2003
[Oral combination chemotherapy of 5'-deoxy-5-fluorouridine (furtulon) and cyclophosphamide for advanced breast cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2003, Volume: 25, Issue:3

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

2003
Fluorinated pyrimidines in treatment of breast cancer patients with liver metastases.
    Cancer chemotherapy reports, 1963, Volume: 27

    Topics: Breast Neoplasms; Floxuridine; Fluorouracil; Humans; Liver Neoplasms; Pyrimidines

1963
FURTHER CLINICAL COMPARISON BETWEEN 5-FLUOROURACIL (5-FU) AND 5-FLUORO-2' -DEOXYURIDINE (5-FUDR).
    Cancer chemotherapy reports, 1963, Volume: 32

    Topics: Brain Neoplasms; Breast Neoplasms; Diarrhea; Floxuridine; Fluorouracil; Geriatrics; Humans; Liver Ne

1963
PROTRACTED AMBULATORY INFUSION CANCER CHEMOTHERAPY BY THE WATKINS CHRONOMETRIC INFUSOR.
    Cancer chemotherapy reports, 1964, Volume: 37

    Topics: Adenoma; Antineoplastic Agents; Breast Neoplasms; Carcinosarcoma; Colonic Neoplasms; Dermatitis, Exf

1964
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
    JAMA, 1964, Nov-16, Volume: 190

    Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid

1964
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
    Archives of internal medicine, 1965, Volume: 115

    Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo

1965
[PyNPase and DPD expression potentially predict response to 5'-DFUR treatment for node-positive breast cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:9

    Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Dihydrouracil De

2003
A case of chest wall recurrence of breast cancer treated with paclitaxel weekly, 5'-deoxy-5-fluorouridine, arterial embolization and chest wall resection.
    Breast cancer (Tokyo, Japan), 2003, Volume: 10, Issue:4

    Topics: Angiography; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Em

2003
[A case of advanced breast cancer with multiple lung, bone and lymph node metastases successfully treated with 5'-DFUR alone].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Combined Modality Therapy;

2003
Positive response to oral chemoendocrine combination therapy using 5"-deoxy-5-fluorouridine for locally advanced breast cancer with carcinomatous pleurisy: report of a case.
    Surgery today, 2003, Volume: 33, Issue:12

    Topics: Administration, Oral; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Therapy, Combination;

2003
[A case of breast cancer with lung and bone metastasis treated successfully by oral combination chemotherapy of 5'-deoxy-5-fluorouridine and cyclophosphamide].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal,

2003
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
    Journal of the National Cancer Institute, 2004, May-19, Volume: 96, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothe

2004
[A long-surviving patient with Stage IV breast cancer with no recurrence after combined therapy of medroxy progesterone acetate (MPA) and intra-arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9

    Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl

2004
[Combination therapy with Anastrozole and 5'-DFUR as a treatment for metastatic breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:10

    Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas

2004
[Successful combination therapy with 5'-DFUR and MPA for breast cancer with spinal and vertebral metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:13

    Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combine

2004
[Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:13

    Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protoc

2004
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3

    Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl

2005
[Effective reduction of elevated tumor markers by exemestane--a 12-year follow-up of a case of bone metastatic breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3

    Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol

2005
[A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:4

    Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplas

2005
[Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:5

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast

2005
Combination of 5-deoxy-5-fluorouridine and tamoxifen show cell-type specific antagonistic and cooperative effects on cytotoxicity in human mammary carcinoma cells.
    Oncology reports, 2005, Volume: 14, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Dose-Respons

2005
[Experience with capecitabine in patients with anthracycline and/or taxane-resistant recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:8

    Topics: Administration, Oral; Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabin

2005
[Pharmacokinetic comparison of capecitabine and 5'-deoxy-5-fluorouridine (doxifluridine; 5'-DFUR)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:13

    Topics: Antimetabolites, Antineoplastic; Area Under Curve; Breast Neoplasms; Capecitabine; Clinical Trials,

2005
Analysis of mechanisms contributing to AraC-mediated chemoresistance and re-establishment of drug sensitivity by the novel heterodinucleoside phosphate 5-FdUrd-araC.
    Apoptosis : an international journal on programmed cell death, 2006, Volume: 11, Issue:3

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cytarabi

2006
Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5'-DFUR in breast cancer MCF7 cells.
    Biochemical pharmacology, 2006, Dec-15, Volume: 72, Issue:12

    Topics: Antimetabolites, Antineoplastic; Biological Transport; Breast Neoplasms; Cell Cycle; Cell Line, Tumo

2006
5-FdUrd-araC heterodinucleoside re-establishes sensitivity in 5-FdUrd- and AraC-resistant MCF-7 breast cancer cells overexpressing ErbB2.
    Differentiation; research in biological diversity, 2006, Volume: 74, Issue:9-10

    Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Caspase 7; Cell Cycle; Cell Proliferat

2006
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine

2007
5-Fluorouracil incorporation in DNA of human breast carcinoma cells.
    Cancer research, 1982, Volume: 42, Issue:8

    Topics: Breast Neoplasms; Cell Line; DNA Replication; DNA, Neoplasm; Female; Floxuridine; Fluorouracil; Huma

1982
The potential for clinical application of in vitro assays predicting 5-FU sensitivity in man.
    Cancer treatment reports, 1981, Volume: 65 Suppl 3

    Topics: Breast Neoplasms; Cell-Free System; Cytosol; Floxuridine; Fluorodeoxyuridylate; Fluorouracil; Humans

1981
5'-Deoxy-5-fluorouridine selective toxicity for human tumor cells compared to human bone marrow.
    Cancer research, 1983, Volume: 43, Issue:6

    Topics: Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cell Survival; Colonic Neoplasms; Floxuridine;

1983
Cytotoxic activity of 5'-deoxy-5-fluorouridine in cultured human tumors.
    Cancer treatment reports, 1983, Volume: 67, Issue:6

    Topics: Breast Neoplasms; Cell Line; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Female;

1983
[Phase I study of a new floxuridine derivative, 2'-deoxy-3', 5'-di-O-acetyl-5-fluoro-3-(3-methylbenzoyl)uridine (FF-705)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:1

    Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Drug Administration Schedule; Drug Ev

1984
[Phase II study of FF-705 by Clinical Cooperative Study Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:1

    Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Drug Administratio

1984
Uracil enhancement of 5-fluorodexoyuridine incorporation into human breast carcinoma deoxyribonucleic acid.
    Biochemical pharmacology, 1984, Jul-15, Volume: 33, Issue:14

    Topics: Breast Neoplasms; Cells, Cultured; DNA, Neoplasm; Female; Floxuridine; Humans; RNA, Neoplasm; Uracil

1984
[Effects of 5'-deoxy-5-fluorouridine on human gastrointestinal and breast cancers xenografted to nude mice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Animals; Breast Neoplasms; Carcinoma; Colonic Neoplasms; Femal

1984
Combined effects of methotrexate and 5-fluoropyrimidine on human breast cancer cells in serum-free culture.
    European journal of cancer, 1980, Volume: 16, Issue:5

    Topics: Breast Neoplasms; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Floxur

1980
Evaluation of plasma 5-fluorouracil nucleoside levels in patients with metastatic breast cancer: relationships with toxicities.
    Cancer chemotherapy and pharmacology, 1995, Volume: 37, Issue:1-2

    Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Female; Floxuridine; Fluorouracil; Humans;

1995
Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase.
    British journal of cancer, 1995, Volume: 72, Issue:3

    Topics: Antineoplastic Agents; Biological Availability; Breast; Breast Neoplasms; Cell Communication; Cell D

1995
[A case of recurrent breast cancer responding to combination therapy with mitoxantrone (MIT), 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:14

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplas

1994
[A case of complete response of breast cancer with pulmonary metastases to combination therapy of 5'-DFUR and MPA].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:15

    Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Female; Floxuridine; Humans; Lu

1994
[A case of advanced breast cancer with multiple lung metastases responding well to postoperative combined administration of doxifluridine (5'-DFUR) and tamoxifen].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:8

    Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; F

1994
[A case of inflammatory breast cancer successfully treated with 5'-DFUR and MPA].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:12

    Topics: Administration, Oral; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Floxuridine; Humans; Ma

1994
[A histological observation after a short-term administration of 5'-DFUR and tamoxifen in patients with advanced breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:13

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo

1993
[A case of long surviving inflammatory breast cancer with bone metastasis, treated by intra-arterial infusion chemotherapy followed by extended mastectomy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Female; Floxuridine; Humans;

1993
[Preoperative intra-arterial injection of mitoxantrone for locally advanced breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Administration, Oral; Adult; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule;

1993
[A case of breast cancer with multiple organ metastases in which single low dose administration of 5'-DFUR proved effective].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Female; Floxuridine; Humans;

1993
[Influences of 5'-deoxy-5-fluorouridine (5'-DFUR) on cell cycle in patients with breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:6

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; DNA, Neoplasm; Female; Flow Cytometry; Floxurid

1993
[Usefulness of contact thermography for the evaluation of chemotherapeutic effectiveness in breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc

1993
[A case of recurrent breast cancer responding to long-term treatment with 5'-DFUR combined with MPA].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:9

    Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Ad

1996
[Intra-arterial infusion chemotherapy for liver metastases from breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedul

1996
[A case resectable hepatic metastases of breast cancer following intrahepatic arterial chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Femal

1996
Potent growth inhibitory activity of zidovudine on cultured human breast cancer cells and rat mammary tumors.
    Cancer research, 1997, Jun-15, Volume: 57, Issue:12

    Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Division; Dose-Response Relationshi

1997
[A case of advanced breast cancer receiving combination therapy with 5'-DFUR and MPA with remarkable results].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:9

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Papillary; Combin

1997
[Efficacy of combination chemotherapy of cyclophosphamide and 5'-deoxy-5-fluorouridine in a mammary tumor xenograft model, MX-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cyclophosp

1997
[Complete tumor regression obtained by chemoendocrine therapy including toremifene in two cases of pulmonary metastasis of breast cancer with a history of tamoxifen treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide;

1997
[Efficacy of combination chemotherapy with mitoxantrone, vincristine, doxifluridine and prednisolone for recurrence of breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:15

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

1997
[Intra-arterial injection therapy of mitoxantrone for locally advanced breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling; Combined Mo

1998
[Comparative study of 5'-DFUR administration of single time per day versus two or three times].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:11

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Drug Administration Sche

1998
[A case of stage IV breast cancer showing long-term complete response to combination therapy with 5'-DFUR and MPA].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:13

    Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Ne

1998
[A case of giant advanced breast cancer responding remarkably to chemo-endocrine therapy chiefly with doxifluridine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:14

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, D

1998
[Comparative study of 5'-deoxy-5-fluorouridine between older cancer patients versus younger cancer patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:4

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Colonic Neopla

1999
Comparison of paclitaxel-, 5-fluoro-2'-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis.
    The Journal of biological chemistry, 1999, May-28, Volume: 274, Issue:22

    Topics: Affinity Labels; Antineoplastic Agents; Apoptosis; Apoptotic Protease-Activating Factor 1; Breast Ne

1999
[Effective chemo-endocrine combination therapy for obstructive-jaundice caused by multiple liver metastasis of recurrent breast cancer--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:7

    Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla

1999
[Endocrine chemotherapy (high-dose toremifene + 5'-DFUR) found markedly effective for 2 cases of metastatic breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Female; Flox

1999
[A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:8

    Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combine

1999
[A case of adriamycin and methotrexate-resistant recurrent breast cancer treated with doxifluridine and mitomycin C].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:9

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco

1999
[A breast cancer patient with docetaxel-resistant pleural recurrence with remarkable response to doxifluridine and cyclophosphamide].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:9

    Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc

1999
[Doxifluridine decreases serum levels of interleukin-6 in a cancer cachexia model].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:10

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cachexia; Cell Division; Female; Floxuridine; Huma

1999
[Successful endocrine chemotherapy in patients with multiple bone metastases of breast cancer--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Combined Modality

1999
[A case of intra-arterial infusion chemotherapy for liver metastases of breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, P

1999
[Successful treatment of pleuritis carcinomatosa using combination therapy of 5'-DFUR, MPA and CPA as maintenance therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:13

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide;

1999
[A case of recurrent breast cancer with carcinoma erysipeloides responding to sequential therapy with docetaxel (TXT) and doxifluridine (5'-DFUR) accompanied by leucovorin (LV)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:4

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

2000
[Pain relief with alendronate therapy in a breast cancer patient with bone metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:4

    Topics: Aged; Alendronate; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Breast Ne

2000
[Efficacy of combined chemoendocrine therapy with doxifluridine, cyclophosphamide, and fadrozole hydrochloride hydrate in a case of stage T4N3M1 breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:5

    Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclop

2000
[Chemotherapy with mitoxantrone for the treatment of recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Drug Administratio

2000
[A case of effective bisphosphonate therapy of sequential pamidronate and incadronate for bone metastases from breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dr

2000
Intratumoral pyrimidine nucleoside phosphorylase (PyNPase) activity predicts a selective effect of adjuvant 5'-deoxy-5-fluorouridine (5'DFUR) on breast cancer.
    Breast cancer (Tokyo, Japan), 2000, Volume: 7, Issue:1

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combin

2000
A case of metastatic breast cancer achieving complete response by combination therapy with 5'-deoxy-5-fluorouridine and cyclophosphamide.
    Breast cancer (Tokyo, Japan), 2000, Volume: 7, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Carcinoma, Duct

2000
Correlation between elevated intratumoral thymidine phosphorylase and prognosis of node-positive breast carcinoma undergoing adjuvant doxifluridine treatment.
    International journal of oncology, 2000, Volume: 17, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemother

2000
[A case of advanced breast cancer that responded remarkably to chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide;

2000
[A case of breast cancer with multiple organ metastases responding remarkably to combination therapy of CAF (cyclophosphamide, adriamycin and 5-FU), 5'-DFUR and MPA (medroxyprogesterone acetate)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:14

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined M

2000
[Advanced breast cancer with multiple bone metastases successfully treated with combined chemoendocrine-therapy of CEF (cyclophosphamide, epirubicin, 5-fluorouracil) and 5'-DFUR (5'-deoxy-5-fluorouridine) + MPA (medroxyprogesterone acetate)--a case report
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre

2001
Progression and enhancement of metastatic potential after exposure of tumor cells to chemotherapeutic agents.
    Cancer research, 2001, Apr-01, Volume: 61, Issue:7

    Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Divisi

2001
Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidi

2001
[A patient with recurrent breast cancer whose liver metastasis regressed following combined use of weekly docetaxel and MPA.5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast;

2001
Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cachexia; Docetaxel; Drug Interactions;

2001
[Hepatic infusion of docetaxel using PEIT for a patient with stage IV breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:12

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

2001
Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:1

    Topics: Affinity Labels; Animals; Antibodies, Monoclonal; Antibody Formation; Antimetabolites, Antineoplasti

2002
[A 5'-DFUR + CPA + THP therapy that was effective for paclitaxel-refractory pulmonary metastasis of breast cancer--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:1

    Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

2002
[Antimetastatic and antitumor effects of fluoropyrimidines alone and combined with taxanes in a murine model of breast cancer metastatic to the lung].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:1

    Topics: Aminoacridines; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea

2002
[A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2

    Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bre

2002
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
    Angiogenesis, 2001, Volume: 4, Issue:3

    Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc

2001
[Successful treatment of advanced recurent breast cancer using DMpC therapy as maintenance therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophospha

2002
[A case of breast cancer with multiple bone metastases that responded remarkably to doxifluridine (5'-DFUR), cyclophosphamide (CPA), medroxyprogesterone acetate (MPA) and pamidronate disodium therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide;

2002
[The antitumor activity of DPD inhibitory-fluoropyrimidine (DIF) and non-DIF alone or in combination with paclitaxel against orthotopically implanted human breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:5

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Di

2002
Thymidine labeling index of human breast carcinoma. Enhancement of in vitro labeling by 5-fluorouracil and 5-fluoro-2'-deoxyuridine.
    Cancer, 1977, Volume: 39, Issue:6

    Topics: Breast Neoplasms; DNA, Neoplasm; Female; Floxuridine; Fluorouracil; Humans; In Vitro Techniques; Met

1977
Phase I study of 5-fluorodeoxyuridine plus cytosine arabinoside infusions in patients with solid tumors.
    Cancer treatment reports, 1979, Volume: 63, Issue:8

    Topics: Adolescent; Adult; Aged; Breast Neoplasms; Cytarabine; Drug Administration Schedule; Drug Evaluation

1979
[A case of advanced breast cancer responding to low-dose 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:7

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female;

1992
[Successful treatment of disseminated breast cancer with combination therapy of 5'-deoxy-5'-fluorouridine (5'-DFUR), medroxyprogesterone acetate (MPA) and cyclophosphamide (CPA)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Papillary; Cyclophospha

1992
Programmed cell death in an estrogen-independent human breast cancer cell line, MDA-MB-468.
    Cancer research, 1992, Jun-15, Volume: 52, Issue:12

    Topics: Breast Neoplasms; Cell Death; Cell Division; Cell Membrane; DNA Damage; DNA, Neoplasm; Female; Floxu

1992
Interleukin-6 and 12-O-tetradecanoyl phorbol-13-acetate act synergistically in inducing cell-cell separation and migration of human breast carcinoma cells.
    Cytokine, 1991, Volume: 3, Issue:3

    Topics: 8-Bromo Cyclic Adenosine Monophosphate; Alkaloids; Antibodies, Monoclonal; Breast Neoplasms; Carcino

1991
[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female;

1991
[5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colonic Neop

1991
Infusion of floxuridine plus etoposide plus cisplatin in human malignancies.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci

1991
[Combination therapy with 5'DFUR and MPA as a second line treatment for advanced/recurrent breast cancer].
    Nihon Gan Chiryo Gakkai shi, 1990, Mar-20, Volume: 25, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Floxuridine;

1990
[The study of 5-FU levels and pyrimidine nucleoside phosphorylase (PyNPase) activity in human breast cancer tissue after administration of 5'-deoxy-5-fluorouridine (5'-DFUR)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:7

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Mid

1990
[A study on pre-operative administration of 5'-DFUR in carcinomas of the gastric, breast, thyroid and colon].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:12

    Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Colonic Neoplasms; Combined Modality Therapy; F

1990
Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates.
    The Journal of biological chemistry, 1985, Aug-15, Volume: 260, Issue:17

    Topics: Breast Neoplasms; Cell Line; Female; Floxuridine; Humans; Kinetics; Macromolecular Substances; Mathe

1985
Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells.
    Cancer research, 1986, Volume: 46, Issue:9

    Topics: Azacitidine; Breast Neoplasms; Cell Line; Cell Survival; Decitabine; Deoxycytidine; Deoxyuridine; DN

1986
Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate.
    The Journal of biological chemistry, 1987, Oct-05, Volume: 262, Issue:28

    Topics: Acyltransferases; Antineoplastic Agents; Breast Neoplasms; Carbon Radioisotopes; Cell Line; Female;

1987
[The serum and tissue concentration of FT-207, 5'-DFUR and 5-FU in patients with breast cancer by preoperative administration of UFT and 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Floxuridine; Fluorouracil;

1989
[Intracellular localization of halogenated drugs or molecules in cultured tumor cells. A study using ionic microscopy associated with an imaging processing system].
    Bulletin du cancer, 1989, Volume: 76, Issue:8

    Topics: Breast Neoplasms; Bromodeoxyuridine; Cells, Cultured; Female; Floxuridine; Humans; Image Processing,

1989
[Effect of combination chemotherapy of 5'-DFUR, cyclophosphamide and tamoxifen in a case of advanced breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:1

    Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C

1989
[A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:10

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Capsules; Diar

1985
[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:10

    Topics: Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Administration

1985
[Phase II study of 5'-DFUR in gastrointestinal and breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarr

1985
[Phase II study of 5'-DFUR (5'-deoxy-5-fluorouridine) by the Cooperative Study Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:11

    Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neopla

1985
[Diagnosis of minimal breast cancer by diagnostic hormonal treatment].
    Gan no rinsho. Japan journal of cancer clinics, 1986, Volume: 32, Issue:4

    Topics: Adult; Androstanols; Breast; Breast Neoplasms; Female; Fibrocystic Breast Disease; Floxuridine; Huma

1986
Phase II clinical evaluation of doxifluridine.
    Cancer treatment reports, 1986, Volume: 70, Issue:6

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Central Nervous System Diseases; Col

1986
[Clinical trial of 5'-deoxy-5-fluorouridine in malignant tumors under cooperative study (phase II study)].
    Nihon Gan Chiryo Gakkai shi, 1986, Jun-20, Volume: 21, Issue:5

    Topics: Aged; Aged, 80 and over; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation; Female; Floxuridine;

1986
[Combination chemotherapy of human gastrointestinal and breast cancer xenografts in nude mice with 5'-deoxy-5-fluorouridine and mitomycin C].
    Nihon Gan Chiryo Gakkai shi, 1986, Aug-20, Volume: 21, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female

1986
[Combination chemotherapy with 3 or 4 drugs on human breast and gastrointestinal cancer xenografts in nude mice (II)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:5 Pt 1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla

1987
[Effects of alternating chemotherapy with 2 non-cross-resistant drug combinations on human alimentary and breast cancer xenografts in nude mice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:5 Pt 1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neopla

1987
Catheter perforation of the duodenum during hepatic artery chemotherapy.
    Gastrointestinal endoscopy, 1987, Volume: 33, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catheters, Indwelling; Doxo

1987
[A new anticancer drug, 5'-deoxy-5-fluorouridine (5'-DFUR)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Floxuridine; Humans;

1987
A phase II study of doxifluridine in patients with advanced breast cancer.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Floxuridine; Humans;

1988
[Clinical trial of 5'-DFUR in patients with recurrent breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:10

    Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Drug Administration Schedule; Female; Floxuridi

1988
[Clinical phase II study of 5'-DFUR for cancer of the digestive organs by a cooperative study group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:12

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colo

1985
Gastroduodenal ulcerations in patients receiving selective hepatic artery infusion chemotherapy.
    The American journal of gastroenterology, 1985, Volume: 80, Issue:6

    Topics: Adult; Aged; Breast Neoplasms; Female; Floxuridine; Gastroscopy; Humans; Infusions, Intra-Arterial;

1985
Antitumor activity of a new fluoropyrimidine derivative, 5'-deoxy-5-fluorouridine, against murine and human experimental tumors.
    Japanese journal of cancer research : Gann, 1985, Volume: 76, Issue:7

    Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Floxuridine; Humans; Leukemia L1210; Leuke

1985
[Clinical effect of 5'-deoxy-5-fluorouridine (5'-DFUR)].
    Gan no rinsho. Japan journal of cancer clinics, 1985, Volume: 31, Issue:6 Suppl

    Topics: Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Ev

1985
Systemic chemotherapy of mammary carcinoma.
    Annals of surgery, 1971, Volume: 173, Issue:6

    Topics: Amines; Antineoplastic Agents; Azirines; Azo Compounds; Breast Neoplasms; Caproates; Carbohydrates;

1971
The value of fluorinated pyrimidines in advanced malignancy.
    British journal of cancer, 1968, Volume: 22, Issue:4

    Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Female; Floxuridine; Fluorouracil; Humans; Leu

1968
Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520).
    Cancer chemotherapy reports, 1971, Volume: 55, Issue:2

    Topics: Blood Cell Count; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Deoxyuridine; Female; Floxuridin

1971
Continuous intravenous infusions of 5-fluoro-2'-deoxyuridine in the treatment of solid tumors.
    Cancer, 1973, Volume: 31, Issue:4

    Topics: Breast Neoplasms; Diarrhea; Drug Eruptions; Female; Floxuridine; Gastrointestinal Neoplasms; Hemangi

1973
Evaluation of a cell-mediated cytotoxicity assay utilizing 125 iododeoxyuridine-labeled tissue-culture target cells.
    National Cancer Institute monograph, 1973, Volume: 37

    Topics: Adult; AKR murine leukemia virus; Animals; Antigens, Neoplasm; Breast Neoplasms; Cell Line; Cells, C

1973
The clinical effects of prolonged intravenous infusion of 5-fluoro-2'-deoxyuridine.
    Cancer research, 1965, Volume: 25, Issue:7

    Topics: Adenoma, Islet Cell; Aged; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Female; Fl

1965